In contrast to the CIN+ OVCAR-3 tumor model, the KIF18A inhibitors showed no effect on CAL-51 tumor growth, while gemcitabine was efficacious with 75% TGI (P value = 6.7 × 10−19; Fig. 5d). This evidence concerns the gene KIF18A and neoplasm.